生化基因 BIIB 深 沪
等待开盘 05-12 09:30:00 美东时间
198.24
+4.930
+2.55%
华盛通- 最 高200.31
- 今 开194.76
- 成交量 59.13万股
- 最 低 188.30
- 昨 收 193.31
- 总市值 2894.30万
- 52周最高 202.41
- 市盈率 静 19.06
- 换手率 404.99%
- 52周最低 121.06
- 委 比 -87.92%
- 总股本 0.00亿
- 历史最高 468.55
- 量 比 2.12
- 振 幅 6.21%
- 历史最低 0.00
- 每 手 1
- 风险率 24.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
04-18 02:20
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technology, expanding its pipeline.
04-07 20:54
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
04-06 18:40
Biogen Flags $34M R&D Charge to Hit Q1 Earnings by $0.19 Per Share
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on
04-06 18:34
Biogen Presents Additional Results From Phase 1b Study Of Salanersen
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen is a novel
03-11 20:04
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings
Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarte...
02-09 21:36
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump
Biogen beat fourth-quarter earnings and revenue estimates as growth from Leqembi, Skyclarys, and Zurzuvae offset declining multiple sclerosis sales, while the company forecast higher 2026 earnings.
02-06 23:33
Earnings Summary: Biogen Q4
Biogen (NASDAQ:BIIB) announced its Q4 earnings on Friday, February 6, 2026 at 0...
02-06 19:06
Amazon, AutoNation And 3 Stocks To Watch Heading Into Friday
U.S. stock futures down; AutoNation, Amazon, Philip Morris, Reddit, and Biogen expected to report quarterly earnings.
02-06 14:41
